Artelo Biosciences Announces Proposed Underwritten Public Offering
AI-Generated Summary
Artelo Biosciences, a clinical-stage pharmaceutical company, has announced the commencement of an underwritten public offering of its common stock and/or pre-funded warrants. The offering is solely by the company and is managed by R.F. Lafferty & Co., Inc. This capital raise is subject to market conditions, with no assurance on its completion, size, or terms.
In a nutshell
This public offering represents a strategic move by Artelo Biosciences to raise capital, likely to fund its ongoing clinical-stage research and development in lipid-signaling pathways for various conditions. For a clinical-stage pharmaceutical company, securing additional financing is a crucial step to advance its pipeline and operations.
Source: The Manila Times
